• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

    3.045 -0.055 (-1.77%)
    Streaming Delayed Price Updated: 10:13 AM EDT, Sep 26, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Cassava Sciences, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    38 39 Next >
    Cassava Sciences Reports Q3 2024 Financial and Operating Results
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Unpacking the Latest Options Trading Trends in Cassava Sciences
     
    Via Benzinga
    Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
    Conference call and webcast to begin at 8:30 AM ET 
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Analysts Believe Cassava Sciences Now Has 300% Upside From Here
    Cassava Sciences faces controversy over its Alzheimer's drug, simufilam, amid fraud allegations, yet analysts maintain a Buy rating with high upside potential. 
    Via MarketBeat
    Topics Fraud Lawsuit
    How Is The Market Feeling About Cassava Sciences?
     
    Via Benzinga
    $1000 Invested In This Stock 5 Years Ago Would Be Worth $20,000 Today
     
    Via Benzinga
    Cassava Sciences Unusual Options Activity
     
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
     
    Via Benzinga
    Crude Oil Falls Over 4%; US Trade Deficit Narrows In August
     
    Via Benzinga
    What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday?
    Cassava Sciences Inc. has agreed to a $40 million settlement over SEC charges related to misleading data for simufilam. The firm anticipates top-line results from the ReTHINK Phase 3 trial before... 
    Via Benzinga
    Topics Regulatory Compliance
    PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday
     
    Via Benzinga
    This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
     
    Via Benzinga
    Here's How Much $100 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today
     
    Via Benzinga
    Market Whales and Their Recent Bets on SAVA Options
     
    Via Benzinga
    Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
    Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set... 
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
     
    Via Benzinga
    Why Cassava Sciences Stock Dived by Almost 11% Today
    Without admitting wrongdoing, the company put a regulatory controversy to rest, but this was expensive. 
    Via The Motley Fool
    Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
     
    Via Benzinga
    SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty
    Cassava Sciences and its executives face a $40 million SEC settlement over manipulated data in an Alzheimer's drug trial, misleading investors with false claims of cognitive improvement and selective... 
    Via Benzinga
    Topics Regulatory Compliance
    12 Health Care Stocks Moving In Friday's Pre-Market Session
     
    Via Benzinga
    Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    Cassava Sciences Resolves SEC Investigation
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Cassava Sciences Stock Rises On Interim Safety Review Of Simufilam Phase 3 Trials
    Cassava Sciences, Inc. (NASDAQ: SAVA) shares trading higher following the announcement of a positive interim safety review of its Alzheimer's drug candidate, simufilam. Here's what you need to know. 
    Via Benzinga
    Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Cassava Sciences Names Rick Barry as Chief Executive Officer
    Claude Nicaise, M.D. appointed Chairman of the Board 
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    9 Health Care Stocks Whale Activity In Today's Session
     
    Via Benzinga
    Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
    Cassava Sciences has become a hot topic among traders due to its recent surge in volatility, liquidity, and overall market performance. 
    Via MarketBeat
    SAVA Stock Earnings: Cassava Sciences Beats EPS for Q2 2024
    SAVA stock results show that Cassava Sciences beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    38 39 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.